The Medicines Company (NASDAQ: MDCO) declared that the U.S. Food and Drug Administration (FDA) has authorised the intravenous (IV) therapy CleviprexTM (clevidipine butyrate) injectable coat for the change of murder push when test therapy is not viable or not desirable. Cleviprex, a new IV antihypertensive, represents an development over currently acquirable therapies, providing fast and fine curb of murder push in the grave tending setting.

Tags: ATM, Current, Medicine